Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.4631
- Book/Share 32.4389
- PB 5.4734
- Debt/Equity 0.6469
- CurrentRatio 1.0059
- ROIC 0.1216
- MktCap 427600767000.0
- FreeCF/Share 6.7781
- PFCF 26.078
- PE 18.9538
- Debt/Assets 0.2625
- DivYield 0.0286
- ROE 0.3039
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit
Published: May 18, 2025 by: Business Wire
Sentiment: Neutral
WASHINGTON & BERLIN--(BUSINESS WIRE)--Association of Medical Device Reprocessors issued the following statement: Friday's unanimous verdict by a federal jury in Santa Ana, California for Innovative Health against Johnson & Johnson (NYSE: JNJ) is a victory for America's hospitals, providers, patients, and the environment. The jury found that Biosense Webster violated federal and state antitrust laws by withholding clinical support to hospitals using Innovative Health's FDA regulated, reproce.
Read More
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
If You Invested $25,000 In Johnson & Johnson (JNJ) 20 Years Ago, This Is How Much Cash From Dividends You Would Have Today
Published: May 15, 2025 by: 24/7 Wall Street
Sentiment: Positive
Companies with strong products, good management, solid earnings and growth trends, and a history of annual dividend increases are often popular buy and hold stocks to take advantage of dividend compounding.
Read More
Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Read More
Johnson & Johnson (JNJ) BofA Securities 2025 Healthcare Conference Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ET Company Participants John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Tim Anderson - Bank of America Tim Anderson I think we're live. Thank you for joining us.
Read More
Johnson & Johnson: For Those Who Want Some Immunity Against Tariff Changes
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Negative
The U.S. and China have agreed to reduce tariffs temporarily for 90 days. I expect continued market volatility in the negotiation process. Johnson & Johnson could offer some immunity due to the specific breakdown of the trade between these two countries and JNJ's relatively minor exposure to China.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Read More
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, Pa. , May 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.
Read More
4 High-Yielding Dogs of the Dow Are Crushing the Major Indices
Published: May 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially high-yield ones, because they offer significant income streams and have substantial total return potential.
Read More
Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
NEW ORLEANS--(BUSINESS WIRE)--A jury has awarded $3 million to the family of Jeanine Henderson, a 72-year-old mother from New Orleans who died from mesothelioma, a rare and incurable cancer caused by asbestos exposure, after a lifetime of using Johnson & Johnson's Baby Powder. After a two-month trial, attorneys from Dean Omar Branham Shirley successfully proved that Ms. Henderson's daily use of the talc-based powder was directly linked to her illness. The legal team also presented clear evi.
Read More
Dividend Hikes Offer Optimism Amid Tariff Turmoil
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Stocks have rebounded sharply off their early-April lows, but macro risks persist. Dividend stocks have largely outperformed so far this year. We profile a pair of blue chips that recently announced dividend hikes, which has turned out to be a broader Q2 theme.
Read More
3 Stable Stocks to Buy When the Price is Right
Published: May 06, 2025 by: Morningstar
Sentiment: Positive
There's no such thing as a safe stock, but these low-volatility names stand up relatively well in shaky markets.
Read More
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Read More
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ and ABBV expect their sales and profits to improve in 2025.
Read More
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older.
Read More
US FDA approves J&J's immune disorder drug
Published: April 30, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.
Read More
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin G (IgG) levels, one of the root causes of gMG, in both the adult and pediatric pivotal studies gMG patients taking IMAAVY demonstrated 20 months of lasting disease control and symptom relief in the pivotal Vivacity-MG3 study and ongoing open-label extension (OLE) SPRING HOUSE, Pa. , April 30, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY™ (nipocalimab-aahu), a …
Read More
3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
Published: April 28, 2025 by: MarketBeat
Sentiment: Positive
In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco Wholesale NASDAQ: COST, and NASDAQ NASDAQ: NDAQ have each announced meaningful hikes to their quarterly payouts, reinforcing their commitment to shareholder value even amid broader market volatility.
Read More
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Published: April 26, 2025 by: PRNewsWire
Sentiment: Neutral
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced first results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. These first results show the promise of TAR-200 in this patient population with more than …
Read More
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 1
Read More
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1
Read More
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
Published: April 26, 2025 by: PRNewsWire
Sentiment: Neutral
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential of TAR-200 to transform outcomes for certain types of BCG-unresponsive, high-risk non-muscle invasive bladder cancer LAS VEGAS , April 26, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from Cohort 2 of the pivotal Phase 2b SunRISe-1 study evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with certain types of bladder cancer. The findings demonstrate the highest complete response rate without reinduction with more than half …
Read More
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Published: April 26, 2025 by: The Motley Fool
Sentiment: Negative
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days.
Read More
Dividend Kings Face-Off: Johnson & Johnson (JNJ) Vs. Procter & Gamble (PG)
Published: April 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
If you are someone who thinks investments should generate regular income, it is important to watch out for dividend stocks.
Read More
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.
Read More
Two Stocks To Consider During Market Unrest To Provide Income Stability
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive
Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price stability and a 3.59% dividend yield, despite potential headwinds from tariffs and economic slowdown. Altria Group, with its 7% yield and Dividend King status, provides stability and potential upside during economic uncertainty, leveraging its pricing power and recession-proof products.
Read More
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer RARITAN, N.J. , April 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100